

POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 62 / 2021

Date of preparation: 2021-11-17

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Termination of the cooperation agreement with Mylan Ireland Ltd.
Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to the information provided in current and interim reports regarding the cooperation of Mabion S.A. (“Company”) with Mylan Ireland Ltd. (“Mylan”), the Management Board of the Company hereby informs that on 17 November 2021 it received a statement from Mylan on the termination of the cooperation agreement (“Agreement”, “Development and Commercialization Agreement”) of which the Company informed in Current Report no. 31/2016 of 8 November 2016. The termination of the Agreement is subject to a 90-day notice period.

The Company reiterates that following an Annex to the Agreement concluded in April 2021, Mylan was only a non-exclusive distribution partner of the Company for MabionCD20 in selected countries in areas such as Australia, New Zealand, Mexico, Central America, southern Africa, southeast Asia. Therefore, the key rights to sell MabionCD20 in the European Union and the United States have been and remain the property of the Company and may be commercialised in the future according to the needs and decisions of the Company.

At present, the termination of the Agreement does not involve any payments or additional financial obligations for the Company. All previous payments between the parties have been settled on the basis of the Annex referred to in Current Report no. 35/2021 of 29 April 2021.

The Company hereby informs that it presently retains full and necessary flexibility to commercialise MabionCD20 in all markets, which may have a positive impact on the acquisition of a strategic investor by the Company, of which the Company informed in Current Report no. 3/2021 of 27 January 2021.